- AstraZeneca stock plunges after late-stage heart drug trial misses its target Quartz —
- Astrazeneca ploughs £300m into UK in surprise U-turn City AM —
- AstraZeneca recommits to £300mn UK investment Financial Times —
- AstraZeneca to inject £300 million into UK in surprise U-turn The Independent —
- Astrazeneca tops expectations in the first quarter on strong cancer drug sales Associated Press —
- AstraZeneca posted stronger-than-expected profit and revenue on surging cancer drug sales Quartz —
- Shot in the arm for GSK and AstraZeneca from cancer drug sales The Argus —
- AstraZeneca beats expectations on cancer drug demand RTE —
- AstraZeneca Gets Revenue Boost From Cancer Drugs Wall Street Journal —
- AstraZeneca sees stock market value slump by more than £20bn after drug setback Yorkshire Post —
- 2026 Another Catalyst Rich Year: AstraZeneca CFO Bloomberg —
- AstraZeneca makes surprise U-turn with £300m pharma investment The Guardian —
- Shot in the arm for GSK and AstraZeneca from cancer drug sales The Standard —
- AstraZeneca beats top-line and bottom-line estimates; reaffirms FY26 outlook Seeking Alpha —
- AstraZeneca sees stock market value slump by more than £20bn after drug setback The Argus —
- UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies CNBC —
AstraZeneca
British-Swedish pharmaceutical company
AstraZeneca plc (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Also known as...
AstraZeneca plc. and AZ
AstraZeneca Shares Plunge on Drug Trial Failure